Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chitogen was a medical device company specializing in the development of advanced hemostatic products derived from chitosan. The company's flagship product, ChitoGauze, is a flexible hemostatic gauze designed to control moderate to severe bleeding in trauma and surgical settings. Chitogen's technology leverages the naturally mucoadhesive properties of chitosan to promote rapid clot formation and provide antibacterial protection. The company was acquired by HemCon Medical Technologies in 2008 to expand their portfolio of wound care and hemorrhage control solutions. Its products have been widely adopted by military and emergency medical services for hemorrhage control. The acquisition allowed for the integration of Chitogen's gauze technology with HemCon's existing chitosan-based bandage line.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chitogen.